VolitionRx Ltd Files Definitive Proxy Statement
Ticker: VNRX · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 93314
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
Related Tickers: VNRX
TL;DR
VNRX proxy statement out. Vote your shares!
AI Summary
VolitionRx Ltd filed its definitive proxy statement on April 29, 2025, for its annual meeting. The filing details the company's governance and executive compensation practices. Key proposals likely include the election of directors and the ratification of independent auditors.
Why It Matters
This filing provides shareholders with crucial information regarding company leadership and voting matters, enabling informed participation in corporate governance.
Risk Assessment
Risk Level: low — A DEF 14A filing is a routine disclosure and does not inherently represent new financial risk.
Key Numbers
- 001-36833 — SEC File Number (Identifies the company's registration with the SEC.)
Key Players & Entities
- VOLITIONRX LTD (company) — Registrant
- 0001477932-25-003069 (filing_id) — Accession Number
- 20250429 (date) — Filing Date
- 20250424 (date) — Period of Report
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit shareholder votes for their annual or special meetings, providing details on matters to be voted upon, director nominees, and executive compensation.
When was this proxy statement filed?
This definitive proxy statement was filed on April 29, 2025.
What is the company's Central Index Key (CIK)?
VolitionRx Ltd's Central Index Key is 0000093314.
What is the company's business address?
The company's business address is 1489 West Warm Springs Road, Suite 110, Henderson, NV 89014.
What is the SIC code for VolitionRx Ltd?
The Standard Industrial Classification (SIC) code for VolitionRx Ltd is 2835, which corresponds to 'In Vitro & In Vivo Diagnostic Substances'.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding VOLITIONRX LTD (VNRX).